Lilly's Alimta wins maintenance use in NSCLC; Thalidomide victims sue, claiming drugmakers hid risks;

@FiercePharma: Back-to-school sales of Shire's ADHD meds help boost Q3 sales by 24% Story | Follow @FiercePharma

> Eli Lilly's drug Alimta won a new indication in Europe, as a single-agent maintenance therapy for patients with advanced non-small cell lung cancer. Report

> Americans born with birth defects from 1957 to 1962 sued Germany's Grunenthal and two other companies that marketed Thalidomide, saying the drugmakers hid studies that would have pointed up the drug's risks. Article

> Genzyme's new chief David Meeker remarked on the "fundamentally different" culture he's observed at Genzyme and its new parent Sanofi, which plans to operate the biotech as a separate unit. Item

> The market for breast cancer drug treatments in 7 countries will drop this year to $9.3 billion, thanks to generic competition for key drugs, but sales will grow to $10.6 billion by 2020, says a new report. Piece

> Bosnia's Bosnalijek posted a 12% decline in third-quarter profits on lower domestic sales and a bad-debt charge. Report

> Contractors broke ground in Cambridge, MA, on the two buildings that will anchor Biogen Idec's new campus. News

Biotech News

@FierceBiotech: Vertex advancing all-oral Hep C pipeline amid big 3Q profits. Story | Follow @FierceBiotech

@JohnCFierce: Keryx kidney drug fails study (from yesterday). More | Follow @JohnCFierce

@RyanMFierce: Mike Hunkapiller starting new exec chairman role at struggling PacBio. Article | Follow @RyanMFierce

> Gilead asks FDA to approve blockbuster hopeful Quad against HIV. News

> Vertex advancing all-oral Hep C pipeline amid big 3Q profits. Item

Special Report Round-up

> 10 Promising Therapeutic Vaccines. Report

> 5 unusual medtech logos. Report

> 15 top blockbuster contenders. Report

> 10 largest U.S. patent losses. Report

> Biotech's 5 key attacks on pancreatic cancer. Report

> 5 device/diagnostic companies to watch. Report

> Top 10 Standout CMOs. Report

> 5 emerging biotech IT firms to watch. Report

And Finally... Taking two aspirin a day for two years cuts colorectal cancer risk by 60%. Report

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.